Jung-Hee Ryu1, Jae-Hun Kim1, Kum-Suk Park1, Sang-Hwan Do2. 1. Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, South Korea; Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, South Korea. 2. Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, South Korea; Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do 463-707, South Korea. Electronic address: shdo@snu.ac.kr.
Abstract
STUDY OBJECTIVE: To compare the efficacy of remifentanil-propofol with that of fentanyl-propofol for monitored anesthesia care during hysteroscopy. DESIGN: Prospective, randomized study. SETTING:Operating room and postanesthesia care unit of a university hospital. PATIENTS: 30 ASA physical status I and II adult patients undergoing hysteroscopic procedures. INTERVENTIONS: After propofol infusion, patients received a bolus of remifentanil (group R, 0.5 microg/kg) or fentanyl (group F, 1 microg/kg) 4 minutes before starting the procedure and then received a continuous infusion of remifentanil (group R, 0.05 microg/kg per min) or bolus doses of fentanyl (group F, 0.5 microg/kg). MEASUREMENTS AND MAIN RESULTS: Patients in group R had lower pain scores than patients in group F (0-0 vs 0-7, P < 0.05) and more stable blood pressures (74 +/- 15 vs 85 +/- 9 mmHg, P < 0.05) one minute after the start of the procedure. However, no differences were observed in other variables (recovery profiles and satisfaction scores). CONCLUSION:Remifentanil seems to be a safe and effective analgesic adjunct for monitored anesthesia care of hysteroscopic surgery.
RCT Entities:
STUDY OBJECTIVE: To compare the efficacy of remifentanil-propofol with that of fentanyl-propofol for monitored anesthesia care during hysteroscopy. DESIGN: Prospective, randomized study. SETTING: Operating room and postanesthesia care unit of a university hospital. PATIENTS: 30 ASA physical status I and II adult patients undergoing hysteroscopic procedures. INTERVENTIONS: After propofol infusion, patients received a bolus of remifentanil (group R, 0.5 microg/kg) or fentanyl (group F, 1 microg/kg) 4 minutes before starting the procedure and then received a continuous infusion of remifentanil (group R, 0.05 microg/kg per min) or bolus doses of fentanyl (group F, 0.5 microg/kg). MEASUREMENTS AND MAIN RESULTS:Patients in group R had lower pain scores than patients in group F (0-0 vs 0-7, P < 0.05) and more stable blood pressures (74 +/- 15 vs 85 +/- 9 mmHg, P < 0.05) one minute after the start of the procedure. However, no differences were observed in other variables (recovery profiles and satisfaction scores). CONCLUSION:Remifentanil seems to be a safe and effective analgesic adjunct for monitored anesthesia care of hysteroscopic surgery.